The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Dominant‐negative effects of KCNQ2 mutations are associated with epileptic encephalopathy
Abstract
Objective: Mutations in KCNQ2 and KCNQ3, encoding the voltage‐gated potassium channels K V 7.2 and K V 7.3, are known to cause benign familial neonatal seizures mainly by haploinsufficiency. Here, we set out to determine the disease mechanism of 7 de novo missense KCNQ2 mutations that were recently described in patients with a severe epileptic encephalopathy including pharmacoresistant seizures and pronounced intellectual disability. Methods: Mutations were inserted into the KCNQ2 cDNA. Potassium currents were recorded using 2‐microelectrode voltage clamping, and surface expression was analyzed by a biotinylation assay in cRNA‐injected Xenopus laevis oocytes. Results: We observed a clear loss of function for all mutations. Strikingly, 5 of 7 mutations exhibited a drastic dominant‐negative effect on wild‐type K V 7.2 or K V 7.3 subunits, either by globally reducing current amplitudes (3 pore mutations) or by a depolarizing shift of the activation curve (2 voltage sensor mutations) decreasing potassium currents at the subthreshold level at which these channels are known to critically influence neuronal firing. One mutation significantly reduced surface expression. Application of retigabine, a recently marketed K V 7 channel opener, partially reversed these effects for the majority of analyzed mutations. Interpretation: The development of severe epilepsy and cognitive decline in children carrying 5 of the 7 studied KCNQ2 mutations can be related to a dominant‐negative reduction of the resulting potassium current at subthreshold membrane potentials. Other factors such as genetic modifiers have to be postulated for the remaining 2 mutations. Retigabine or similar drugs may be used as a personalized therapy for this severe disease. Ann Neurol 2014;75:382–394
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone
Brown, D. A., & Adams, P. R. (1980) · Nature · doi:10.1038/283673a0 · Cited by 1,444
Jasper's Basic Mechanisms of the Epilepsies
(2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.001.0001 · Cited by 1,143
Pathways modulating neural KCNQ/M (Kv7) potassium channels
Delmas, P., & Brown, D. A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1785 · Cited by 686 · cited 2×
“Examining expression and trafficking of this mutant in neurons will be crucial to understand these processes, as they depend on many factors, including PIP2, calmodulin, or different kinases expressed at different levels in different cell types .(11,20) Most importantly, we show that both S4 mutations exhibit strong d…”
BackgroundModerate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy
Schroeder, B. C., Kubisch, C., Stein, V., & Jentsch, T. J. (1998) · Nature · doi:10.1038/25367 · Cited by 521
KCNQ2 encephalopathy: Emerging phenotype of a neonatal epileptic encephalopathy
Weckhuysen, S., Mandelstam, S., Suls, A., Audenaert, D., Deconinck, T., Claes, L. R. F., Deprez, L., Smets, K., Hristova, D., Yordanova, I., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22644 · Cited by 514
Self-citationPeters, H. C., Hu, H., Pongs, O., Storm, J. F., & Isbrandt, D. (2005) · Nature Neuroscience · doi:10.1038/nn1375 · Cited by 423
Targeted next generation sequencing as a diagnostic tool in epileptic disorders
Lemke, J. R., Riesch, E., Scheurenbrand, T., Schubach, M., Wilhelm, C., Steiner, I., Hansen, J., Courage, C., Gallati, S., Bürki, S., et al. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03516.x · Cited by 332
Self-citationSingh, N. A. (2003) · Brain · doi:10.1093/brain/awg286 · Cited by 310
Molecular Determinants of KCNQ (Kv7) K+Channel Sensitivity to the Anticonvulsant Retigabine
Schenzer, A., Friedrich, T., Pusch, M., Saftig, P., Jentsch, T. J., Grötzinger, J., & Schwake, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0128-05.2005 · Cited by 267
Wuttke, T. V., Seebohm, G., Bail, S., Maljevic, S., & Lerche, H. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010793 · Cited by 262
Self-citation
Cited by
The genetic landscape of the epileptic encephalopathies of infancy and childhood
McTague, A., Howell, K. B., Cross, J. H., Kurian, M. A., & Scheffer, I. E. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00250-1 · Cited by 604
Self-citationDrug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios
Zhu, X., Petrovski, S., Xie, P., Ruzzo, E. K., Lu, Y.-F., McSweeney, K. M., Ben-Zeev, B., Nissenkorn, A., Anikster, Y., Oz-Levi, D., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.191 · Cited by 342
Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies
Oyrer, J., Maljevic, S., Scheffer, I. E., Berkovic, S. F., Petrou, S., & Reid, C. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014456 · Cited by 315
Self-citationDe novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy
EuroEPINOMICS, R. E. S., Syrbe, S., Hedrich, U. B. S., Riesch, E., Djémié, T., Müller, S., Møller, R. S., Maher, B., Hernandez-Hernandez, L., Synofzik, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3239 · Cited by 276
Self-citationDevelopmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Miceli, F., Soldovieri, M. V., Ambrosino, P., De Maria, M., Migliore, M., Migliore, R., & Taglialatela, M. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4423-14.2015 · Cited by 191
“2/3 GOF mutations associated with EEs reveals a previously unexplored level of complexity in disease pathogenesis, which requires special attention when investigating the effect of Kv7 modulators on cognitive and other neurodevelopmental outcomes (Weckhuysen et al., 2012; Miceli et al., 2013; Orhan et al., 2014).”
BackgroundInfluentialTreatment during a vulnerable developmental period rescues a genetic epilepsy
Marguet, S. L., Le-Schulte, V. T. Q., Merseburg, A., Neu, A., Eichler, R., Jakovcevski, I., Ivanov, A., Hanganu-Opatz, I. L., Bernard, C., Morellini, F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3987 · Cited by 125
Millichap, J. J., Miceli, F., De Maria, M., Keator, C., Joshi, N., Tran, B., Soldovieri, M. V., Ambrosino, P., Shashi, V., Mikati, M. A., et al. (2017) · Epilepsia · doi:10.1111/epi.13601 · Cited by 103
Jiang, X., Raju, P. K., D'Avanzo, N., Lachance, M., Pepin, J., Dubeau, F., Mitchell, W. G., Bello‐Espinosa, L. E., Pierson, T. M., Minassian, B. A., et al. (2019) · Epilepsia · doi:10.1111/epi.16316 · Cited by 97
Vigil, F. A., Bozdemir, E., Bugay, V., Chun, S. H., Hobbs, M., Sanchez, I., Hastings, S. D., Veraza, R. J., Holstein, D. M., Sprague, S. M., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19857818 · Cited by 51
Targeting Kv7 Potassium Channels for Epilepsy
Perucca, E., & Taglialatela, M. (2025) · CNS Drugs · doi:10.1007/s40263-024-01155-3 · Cited by 43
Carotenuto, L., Keminer, O., Carleo, G., Zaliani, A., Leo, A., Citraro, R., De Sarro, G., Dirkx, N., Kaji, M., Weckhuysen, S., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70119 · Cited by 10
Self-citation
Metadata
- Authors
- Orhan, G., Bock, M., Schepers, D., Ilina, E. I., Reichel, S. N., Löffler, H., Jezutkovic, N., Weckhuysen, S., Mandelstam, S., Suls, A., Danker, T., Guenther, E., Scheffer, I. E., De Jonghe, P., Lerche, H., & Maljevic, S.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-03
- Volume
- 75
- Issue
- 3
- Pages
- 382-394
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1892287811
- Cited by
- 276
- References
- 32
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.